Wilms' tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP.

"ccg co-authored this paper in her capacity as a us government employee but the views expressed are her own and should not be construed to represent those of the department of state or the department of health and human services s1 table (docx) s2 table wt1 expression in vivo additional cohorts (docx) s3 table (docx) s4 table (docx) s5 table (docx) s6 table (docx) s1 data (xlsx) s1 fig huarlt-1 endothelial cells assessed by flow cytometry for mcherry (indicative of lytic reactivation) and gfp fluorescence (consistent with constitutive kshv infection) after de novo bac-16 kshv infection. s4 table (docx) s5 table (docx) s6 table (docx) s1 data (xlsx"

"TD is a consultant at Eureka Therapeutics, Inc. DAS is a consultant to, or has equity in, or is on the Board of: Sellas, Eureka, Pfizer, Repertoire, Sapience, Iovance, Actinium, and Atengen; MSK has filed for patent protections on his behalf for related work and some of these patents are licensed. There are no other relationships or activities that could appear to have influenced the submitted work. The other authors have no competing interests to report."

"Research reported in this publication was supported by the National Institutes of Health (National Center For Advancing Translational Sciences, KL2TR002385 to AEM). AEM was also supported by the Weill Medical College of Cornell University Pathogenesis of Infectious Diseases Training Program, National Institutes of Health, 5T32AI007613-18, as well as Weill Cornell Medicine Mastercard Diversity-Mentorship Collaborative Grants: 87001082, 87001319, and the Ritu Banga Healthcare Disparity Research Award: 87000784. This investigation was also supported by National Institutes of Health (National Cancer Institute RO1 CA250074 to EC and the Diversity Supplement to RO1 CA250074-04 to AEM). Clinical trial AMC066/A5263 was supported by the National Institutes of Health/AIDS Malignancy Consortium (National Cancer Institute U01 CA121947 to EC, SEK, PGR, AEM) and the National Institutes of Health/AIDS Clinical Trial Group (National Institute of Allergy and Infectious Diseases, NIAID, UM1 AI068634 to CBM, RMM, UM1 AI068636 to EC, TBC, MZB). One of the KS cohorts was also collected through funding from the National Institutes of Health (National Cancer Institute UH2/UH3 CA202723 to EC, JM and AS). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, HHS or the Department of State. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."